NEW YORK, Feb. 21, 2017 /PRNewswire/ -- RDD Pharma, a leader in developing treatments for anorectal disorders, announces the patent covering methods for treating fecal incontinence has been granted in Israel. The patent is based on the increase in resting anal pressure via a topical administration of RDD-0315, an alpha-agonist. Patents have already been granted in EU, China and Russia and are pending in U.S., Japan, Australia, Brazil, Canada, and India.
RDD Pharma has also received a notice of allowance in the EU for methods and devices for delivery of pharmaceutical agents related to the Capository™, adding to granted patents in the U.S. and Israel. RDD-1219, using the Capository™, is currently in Phase 3 development in Europe for the treatment of pain associated with chronic anal fissure.